Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance

Evolus (NASDAQ: EOLS) reported Q2 EPS of ($0.12), $0.08 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $84.08 million versus the consensus estimate of $81.89 million.

GUIDANCE:

Evolus sees FY2026 revenue of $330-337 million, versus the consensus of $330.5 million.

For earnings history and earnings-related data on Evolus (EOLS) click here.

You May Also Be Interested In

• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• Synopsys (SNPS) Tops Q3 EPS by 24c; offers guidance
• After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX